OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Updates in Ovarian and Cervical Cancers

home / peer-exchange / gynecologic-cancer
Universal Screening for BRCA1 and BRCA2 Mutations

EP. 1: Universal Screening for BRCA1 and BRCA2 Mutations

November 26th 2014
Prophylactic Oophorectomy for Reducing Ovarian Cancer Risk

EP. 2: Prophylactic Oophorectomy for Reducing Ovarian Cancer Risk

November 26th 2014
Timing of Oophorectomy in Ovarian Cancer

EP. 3: Timing of Oophorectomy in Ovarian Cancer

November 26th 2014
Neoadjuvant Chemotherapy for Ovarian Cancer

EP. 4: Neoadjuvant Chemotherapy for Ovarian Cancer

November 26th 2014
Cytoreductive Surgery for Ovarian Cancer

EP. 5: Cytoreductive Surgery for Ovarian Cancer

November 26th 2014
Goal of Surgery in Ovarian Cancer

EP. 6: Goal of Surgery in Ovarian Cancer

November 26th 2014
Chemotherapy Regimens for Ovarian Cancer

EP. 7: Chemotherapy Regimens for Ovarian Cancer

November 26th 2014
Treatment Options in Ovarian Cancer

EP. 8: Treatment Options in Ovarian Cancer

November 26th 2014
Antiangiogenic Agents in Ovarian Cancer

EP. 9: Antiangiogenic Agents in Ovarian Cancer

November 26th 2014
Intraperitoneal Chemotherapy in Ovarian Cancer

EP. 10: Intraperitoneal Chemotherapy in Ovarian Cancer

November 26th 2014
CA-125 Testing in Ovarian Cancer

EP. 11: CA-125 Testing in Ovarian Cancer

November 26th 2014
Platinum Resistance in Ovarian Cancer

EP. 12: Platinum Resistance in Ovarian Cancer

November 26th 2014
Bevacizumab in Ovarian Cancer

EP. 13: Bevacizumab in Ovarian Cancer

November 26th 2014
Promising Treatments in Ovarian Cancer

EP. 14: Promising Treatments in Ovarian Cancer

November 26th 2014
Cervical Cancer Screening and Prevention

EP. 15: Cervical Cancer Screening and Prevention

November 26th 2014
Bevacizumab in Recurrent Metastatic Cervical Cancer

EP. 16: Bevacizumab in Recurrent Metastatic Cervical Cancer

November 26th 2014
Emerging Therapies in Cervical Cancer

EP. 17: Emerging Therapies in Cervical Cancer

November 26th 2014
Challenges for the Future of Gynecologic Cancers

EP. 18: Challenges for the Future of Gynecologic Cancers

November 26th 2014

Latest Conference Coverage

Final PICCOLO Data Underscore Mirvetuximab Soravtansine’s Efficacy in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer

Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact